舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死疗效比较的Meta分析

目的：应用Meta分析的方法评价舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死的临床疗效和安全性。方法：计算机检索多个中外文献数据库，检索时限均为各数据库建库至2016年10月，查找舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死的随机对照试验相关文献，按Cochrane手册对所纳入的文献进行质量评价，并应用RevMan 5.3软件进行Meta分析。结果：最终纳入13项随机对照试验，合计1244例患者。Meta分析结果显示，舒血宁注射液联合奥扎格雷钠治疗急性脑梗死的临床疗效比值比（OR）合并值为4.51（95%可信区间为3.16～6.44）；神经功能缺损评分疗效加权均数差（WMD）合并值为－0.91（95%可信区间为－5.55～3.72）。结论：舒血宁注射液联合奥扎格雷钠治疗急性脑梗死的临床疗效显著优于单用舒血宁注射液，且未见明显不良反应。但由于现有的研究方法学质量均较低，上述结论仍需要更多大样本、高质量的随机对照试验予以验证。

Meta Analysis of Shuxuening Injections and Their Combination with Ozagrel Sodium in the Treatment of Acute Cerebral Infarction

Objective: To evaluate the efficacy and safety of Shuxuening injections combined with ozagrel sodium versus Shuxuening injections alone in the treatment of acute cerebral infarction (ACI). Methods: A number of Chinese and foreign literature data bases were searched from their establishment to October 2016. All randomized controlled trails (RCTs) about Shuxuening injections and their combination with ozagrel sodium in the treatment of ACI were included. The methodology quality of the included studies was evaluated and the results were analyzed by RevMan 5.3. Results: Thirteen studies were included, involving 1244 patients. Results of meta analysis showed Shuxuening injections combined with ozagrel sodium could improve clinical efficacy [OR=4.51, 95%CI (3.16-6.44), P<0.05] compared with Shuxuening injections alone. There were no significant differences in the aspects of improving neurologic impairment and ADR. Conclusion: Meta analysis shows that Shuxuening injections combined with ozagrel sodium are effective for ACI without obvious ADR. However, due to the limit and quality of the included studies, more well-designed and high-quality randomized double-blind control trials are required to provide more convinced evidence.